Kura Oncology, Inc. (KURA) Stock

Kura Oncology, Inc. (KURA) is a Healthcare stock trading at $11.89 (as of 2026-08-21), with a market capitalization of $1.06B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small-molecule medicines for cancer. Its pipeline includes ziftomenib for genetically defined subsets of acute leukemias and tipifarnib for solid tumors and hematologic indications, and it has a clinical collaboration with Novartis to study tipifarnib with alpelisib in head and neck squamous cell carcinoma.

Understand Kura Oncology, Inc.: how it makes money

Kura Oncology develops small-molecule cancer medicines, including ziftomenib and tipifarnib, for genetically defined subsets of acute leukemias in the United States. It generates revenue through net product revenue and collaboration revenue.

The company reports very high gross margin (98.6%) but a deeply negative operating margin (-431.5%), so operating expenses dominate results until net product revenue and collaboration revenue become large enough to cover costs.

Revenue by segment (latest quarter)
Products$0.0B
Collabs$0.0B

Business quality (Weak): As a clinical-stage biopharmaceutical company, Kura Oncology’s reported revenue is very small in the latest quarter, and the operating loss is very large relative to gross profit, so near-term results appear heavily driven by operating expense levels rather than scale of revenue.

Bull case

  • Gross margin is very high (98.6%) in the latest quarter, suggesting that when revenue is recognized, the gross profit component is strong: Gross margin 98.6% (latest quarter ended 2026-03-31).
  • The pipeline includes lead small-molecule candidates aimed at genetically defined subsets of acute leukemias, including ziftomenib and tipifarnib: Business description notes ziftomenib and tipifarnib as lead candidates and that the pipeline targets genetically defined subsets of acute leukemias.

Bear case

  • Profitability is heavily negative, with operating margin at -431.5%, indicating operating expenses far exceed operating profit in the latest quarter: Operating margin -431.5% (latest quarter ended 2026-03-31).
  • Reported revenue is effectively at zero on a rounded basis (total revenue 0.0B), and one candidate’s specific net product revenue is reported as 0.0B: Financials show revenue_b 0.0; KOMZIFTI Net Product Revenue is 0.0B.
Valuation — source: SEC EDGAR (first-party)
Price$11.89
Market Cap$1.06B
Price / Book21.84
Price / Sales13.53
FCF Yield-47.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$67.48M
Net Margin-412.9%
Revenue Growth (YoY)25.2%
EPS Growth (YoY)57.4%
FCF Growth (YoY)-152.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.41 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($78.35M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTroy Edward Wilson
Employees192
CountryUS
IPO Date2015-09-16

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Spero Therapeutics, Inc. (SPRO)
  • Aytu BioPharma, Inc. (AYTU)
  • Rockwell Medical, Inc. (RMTI)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Fortress Biotech, Inc. (FBIO)
  • Assembly Biosciences, Inc. (ASMB)
  • Nuvation Bio Inc. (NUVB)
  • Tango Therapeutics, Inc. (TNGX)
KURA earnings history · KURA institutional & insider holders · KURA KPIs & operating metrics · KURA financials · KURA investor presentations & press releases · KURA SEC filings · KURA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.